{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T06:07:34Z","timestamp":1749017254822,"version":"3.40.5"},"reference-count":23,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"unspecified","delay-in-days":190,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ASHE"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S2732494X23002024_as1\">\n\t    <jats:title>Objective:<\/jats:title>\n\t    <jats:p>This study aimed to examine the clinical risk factors for cephalosporin resistance in patients with Gram-negative bacteremia caused by <jats:italic>Escherichia coli<\/jats:italic> (EC), <jats:italic>Klebsiella pneumoniae<\/jats:italic> (KP), <jats:italic>Enterobacter cloacae<\/jats:italic> (ENC), and <jats:italic>Pseudomonas aeruginosa<\/jats:italic> (PS).<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2732494X23002024_as2\">\n\t    <jats:title>Methods:<\/jats:title>\n\t    <jats:p>This retrospective cohort study included 400 adults with Gram-negative bacteremia. The goal was to review 100 cases involving each species and approximately half resistant and half susceptible to first-line cephalosporins, ceftriaxone (EC or KP), or cefepime (ENC or PS). Logistic regression was used to identify factors predictive of resistance.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2732494X23002024_as3\">\n\t    <jats:title>Results:<\/jats:title>\n\t    <jats:p>A total of 378 cases of Gram-negative bacteremia were included in the analysis. Multivariate analysis identified significant risk factors for resistance, including admission from a chronic care hospital, skilled nursing facility, or having a history of infection within the prior 6 months (OR 3.00, <jats:italic>P<\/jats:italic> &lt; .0001), requirement for mechanical ventilation (OR 3.76, <jats:italic>P<\/jats:italic> &lt; .0001), presence of hemiplegia (OR 3.54, <jats:italic>P<\/jats:italic> = .0304), and presence of a connective tissue disease (OR 3.77, <jats:italic>P<\/jats:italic> = .0291).<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2732494X23002024_as4\">\n\t    <jats:title>Conclusions:<\/jats:title>\n\t    <jats:p>Patients without the identified risk factors should be strongly considered for receiving ceftriaxone or cefepime rather than carbapenems and newer broad-spectrum agents.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1017\/ash.2023.202","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T10:26:00Z","timestamp":1688984760000},"source":"Crossref","is-referenced-by-count":2,"title":["Risk for primary cephalosporin resistance in Gram-negative bacteremia"],"prefix":"10.1017","volume":"3","author":[{"given":"Princy","family":"John","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1688-5010","authenticated-orcid":false,"given":"Sona","family":"Shahbazian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9372-6737","authenticated-orcid":false,"given":"William D.","family":"Lainhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4360-961X","authenticated-orcid":false,"given":"Justin","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4765-4311","authenticated-orcid":false,"given":"Brian","family":"Mochon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9440-465X","authenticated-orcid":false,"given":"David E.","family":"Nix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"S2732494X23002024_ref5","first-page":"16","article-title":"Risk factors associated with multidrug-resistant pneumonia in nonhospitalized patients","volume":"35","author":"Gidal","year":"2018","journal-title":"Fed Pract"},{"key":"S2732494X23002024_ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07755-y"},{"key":"S2732494X23002024_ref23","first-page":"e4515","article-title":"Postprescription review with threat of infectious disease consultation and sustained reduction in meropenem use over four years","author":"Mani","journal-title":"Clin Infect Dis"},{"key":"S2732494X23002024_ref3","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac211"},{"key":"S2732494X23002024_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jointm.2022.03.003"},{"key":"S2732494X23002024_ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3880-z"},{"key":"S2732494X23002024_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.11.002"},{"key":"S2732494X23002024_ref4","unstructured":"4. Centers for Disease Prevention and Control. COVID-19 reverses progress in fight against antimicrobial resistance in U.S. 2022. https:\/\/www.cdc.gov\/media\/releases\/2022\/s0712-Antimicrobial-Resistance.html#:~:text=The%20report%20from%20the%20Centers,infections%20and%20deaths%20both%20increasing. Accessed November 21, 2022."},{"key":"S2732494X23002024_ref6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02728-15"},{"key":"S2732494X23002024_ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.3927"},{"key":"S2732494X23002024_ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-017-3031-7"},{"key":"S2732494X23002024_ref2","first-page":"629","volume":"399","year":"2019","journal-title":"Lancet"},{"volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","year":"2022","key":"S2732494X23002024_ref9"},{"key":"S2732494X23002024_ref16","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0000000000000192"},{"key":"S2732494X23002024_ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07538-5"},{"key":"S2732494X23002024_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.02.013"},{"key":"S2732494X23002024_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"S2732494X23002024_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"S2732494X23002024_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"S2732494X23002024_ref1","unstructured":"1. Center for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf. Published 2019. Accessed October 1, 2022."},{"journal-title":"Open Forum Infect Dis","article-title":"Risk factors for development of carbapenem resistance among Gram-negative rods","author":"Richter","key":"S2732494X23002024_ref7"},{"key":"S2732494X23002024_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.10.034"},{"key":"S2732494X23002024_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.04.005"}],"container-title":["Antimicrobial Stewardship &amp; Healthcare Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2732494X23002024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T10:26:10Z","timestamp":1688984770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2732494X23002024\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023]]}},"alternative-id":["S2732494X23002024"],"URL":"https:\/\/doi.org\/10.1017\/ash.2023.202","relation":{},"ISSN":["2732-494X"],"issn-type":[{"type":"electronic","value":"2732-494X"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"e121"}}